Amendments to th Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-61 (Canceled)

62. (Currently amended) A compound selected from the group consisting of:

N-[4-[3-(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl)benzoyl-(\$)-glutamic-acid;

N-[4-(N-[2-([2,6-diamino-4(3H)-exopyrimidin-5-yl]thio)ethyl]amino)benzoyl]- S-glutamic acid;

N-[(4-[2-([2,6-diamino-4(3H)-exopyrimidin-5-yl]thio)ethyl]thio)benzoyl]-S-glutamic-acid;

N-[2-(5-[3-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)propyl]-thienoyl)]-(S)-glutamic acid;

N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl)thio]-propyl)-3-methyl-thieno- 2-yl]-L-glutamic acid;

N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl)thio]-propyl)-4-methyl-thieno- 2-yl}-L-glutamic acid;

N-(6[([2,6-diamino-4(3H)-oxopyrimidino-5-yl]thio)-methyl]-4,5,6,7-tetrahydrobenzothieno-2-yl)-S-glutamic acid;

N-(5-[2-([2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]thieno-2-yl)-L-glutamic acid;

N-(4[4-[2-([2,6-Diamino-4(3H)-exopyrimidin-5-yl]thio)ethyl]benzeyl)-L-glutamic acid; and the pharmaceutically acceptable salts thereof.